Anavex Life Sciences Corp. · NASDAQ:AVXL

Anavex Life Sciences — Investor Presentation (2014)

27 slides from Anavex Life Sciences's investor presentation, Jul 13, 2014

  1. Slide 1: Corporate Presentation Spring 2014

    Slide 1: Corporate Presentation Spring 2014

    OTCQB: AVXL Corporate Presentation Spring 2014

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    Safe Harbor This presentation contains forward-looking statements made within the meaning of the Private Securities Litigation Reform Act of 1995 by Anavex Life Sciences Corp. and its representatives. These statements can be identified by introductory words such as ``expects,'' ``plans,'' ``intends,

  3. Slide 3: Alzheimer's Disease

    Slide 3: Alzheimer's Disease

    Alzheimer’s Disease … “… Every 68 seconds someone develops Alzheimer’s” ̶ The Alzheimer’s Association 3

  4. Slide 4: Investment Highlights

    Slide 4: Investment Highlights

    Investment Highlights Lead product ANAVEX PLUS directed to Alzheimer‘s disease, a multibillion dollar, poorly served opportunity ANAVEX PLUS poised to enter Phase 2 program Potential to be 1 of 2 FDA registration trials ANAVEX PLUS has a de-risked regulatory pathway ANAVEX PLUS is a “cocktail ” of t

  5. Slide 5: Stress of Aging

    Slide 5: Stress of Aging

    Stress of Aging … People are living longer, which is good But old age often brings a decline in mental capacity Researchers are looking for ways to slow or halt such decline Stress of aging: Stress in brain cells causes gradual accumulation of damaged proteins causing misfolding of proteins Why is m

  6. Slide 6: Rich Pipeline In Alzheimer's And Oncology

    Slide 6: Rich Pipeline In Alzheimer's And Oncology

    Rich Pipeline In Alzheimer’s And Oncology PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ANAVEX PLUS ALZHEIMER’S ANAVEX 2-73 ALZHEIMER’S EPILEPSY STROKE ANAVEX 3-71 (AF710B) ALZHEIMER’S PARKINSON’S ANAVEX 1-41 PARKINSON’S ALZHEIMER’S DEPRESSION STROKE ANAVEX 1079 CANCER (MELANOMA) INFLAMMATORY & NEUROPATHIC PA

  7. Slide 7: Strong Management and Scientific Advisory Board

    Slide 7: Strong Management and Scientific Advisory Board

    Strong Management and Scientific Advisory Board Christopher U. Missling, PhD, MBA • President & CEO of Anavex • 20 years of healthcare industry experience within large pharmaceutical companies (Hoechst, Aventis), the biotech industry (Curis, ImmunoGen) and investment banking (Deutsche Bank, Brimberg

  8. Slide 8: Strong Management and Scientific Advisory Board

    Slide 8: Strong Management and Scientific Advisory Board

    Strong Management and Scientific Advisory Board Norman Relkin, MD, PhD • Associate Professor of Neurology at the Weill Cornell Medical College and Founding Director of the Weill Cornell Memory Disorders • Over 20 years of clinical trials experience, serving as principal investigator in over 20 thera

  9. Slide 9: What is Alzheimer's Disease (AD)?

    Slide 9: What is Alzheimer's Disease (AD)?

    What is Alzheimer‘s Disease (AD)? Cells within brain (neurons) transport electrical messages to other parts of body using chemical transmitters (neurotransmitters). In Alzheimer’s disease, areas of brain tissue are damaged and some messages do not transmit, causing the symptoms. Eventually leads to

  10. Slide 10: Alzheimer's Disease Stages

    Slide 10: Alzheimer's Disease Stages

    Alzheimer‘s Disease Stages Stages of Increased Alzheimer’s burden Loss of speech; locomotion, Terminal consciousness; death Full-time care needed; Very Severe institutionalized Can no longer take care for Severe self; incontinent, depressed Can no longer manage personal affairs; Moderate agitated, c

  11. Slide 11: Alzheimer's Market Overview

    Slide 11: Alzheimer's Market Overview

    Alzheimer’s Market Overview Changes in Number of Deaths (All Ages) Between 2000 and 2010 Aging strongest predictor 40 million Americans are over the age of 65 80 million Americans over 65 by 2040 Diagnosis accelerating 5 million+ Americans currently diagnosed 11 Sources: Alzheimer’s Association, ICA

  12. Slide 12: Significant Market Potential

    Slide 12: Significant Market Potential

    Significant Market Potential $200 billion spent caring for those suffering from Alzheimer’s disease; expected to reach $1.1 trillion by 2050, given the rapid rise in cases U.S. FDA approved four drugs that only temporarily slow worsening of symptoms for about 6 to 12 months, for about half of patien

  13. Slide 13: Current Challenges in Alzheimer's

    Slide 13: Current Challenges in Alzheimer's

    Current Challenges in Alzheimer‘s Recent failures of both “bapi” (Elan, J&J, Pfizer) and “sola” (Eli Lilly) provide evidence that treating AD may not be as simple as removing Abeta plaques in the brain Free-floating particles of Abeta (oligomers) damage brain cells in conjunction with hyper-phospory

  14. Slide 14: ANAVEX PLUS Targets Key Cellular Survival Protein: Sigma-1 Receptor

    Slide 14: ANAVEX PLUS Targets Key Cellular Survival Protein: Sigma-1 Receptor

    ANAVEX PLUS Targets Key Cellular Survival Protein in Neurodegenerative Diseases: Sigma-1 Receptor (Sig-1R) Accumulation of misfolded proteins in the brain is a common feature of most neurodegenerative diseases, and misfolded proteins cause stress, leading to neuronal impairment Sig-1R is a membrane

  15. Slide 15: ANAVEX PLUS Mechanism of Action in Alzheimer's

    Slide 15: ANAVEX PLUS Mechanism of Action in Alzheimer's

    ANAVEX PLUS Mechanism of Action in Alzheimer‘s: Primary effect of Abeta toxicity: after staying in neurons for too long induction of cell stress ANAVEX PLUS Endogenous Sig-1R expressed to reduce cell stress level Chronic cell stress possibly causing Alzheimer’s disease (high correlation with age) He

  16. Slide 16: ANAVEX 2-73 Significantly Reduces Pathology in Transgenic Model Tg2576

    Slide 16: ANAVEX 2-73 Significantly Reduces Pathology in Transgenic Model Tg2576

    ANAVEX 2-73 Significantly Reduces Pathology in Transgenic Alzheimer's Disease Model Tg2576 10 month-old Tg2576 and WT male mice administered p.o. (oral) with tap water or ANAVEX 2-73 (3 mg/kg/day) After 2 months, tested for place learning in the water- maze Acquisition of memory profiles (a), time i

  17. Slide 17: ANAVEX PLUS Clear Synergistic Effect with Aricept by 80%

    Slide 17: ANAVEX PLUS Clear Synergistic Effect with Aricept by 80%

    … ANAVEX PLUS Clear Synergistic Effect of ANAVEX 2-73 with Aricept® (Donepezil) by 80% ANAVEX PLUS: Potential novel combination drug for Alzheimer’s Presented at AAIC 2012 17

  18. Slide 18: ANAVEX PLUS: Compelling Commercial Opportunity

    Slide 18: ANAVEX PLUS: Compelling Commercial Opportunity

    ANAVEX PLUS: Compelling Commercial Opportunity Both as Symptomatic as well as Potentially Disease-Modifying Agent ∆=2.8 ∆=2.5 ANAVEX PLUS: Combination of ANAVEX 2-73 “Plus” Aricept® (donepezil) = Potential novel combination drug for Alzheimer’s Lower clinical trial risk since one compound Aricept® (

  19. Slide 19: Translation Pre-Clinical Data to Clinical Data

    Slide 19: Translation Pre-Clinical Data to Clinical Data

    Translation Pre-Clinical Data to Clinical Data: Understanding The Disconnect Between Rodents and Humans … … Big Pharma uses a predictive patent protected calibrated Quantitative Systems Pharmacology model (QSP): PF-04995274 (Pfizer) in AD – Predicted clinical outcome of cognitive worsening in POC hu

  20. Slide 20: ANAVEX PLUS Anticipated ADAS-Cog Response

    Slide 20: ANAVEX PLUS Anticipated ADAS-Cog Response

    ANAVEX PLUS Anticipated ADAS-Cog Response of 7 Points at 12 Weeks and 5.5 Points at 26 Weeks – More Than 2X Aricept® (Donepezil) Alone Humanized calibrated realistic cortical network computer model Confirmed pre- clinical unexpected synergy between ANAVEX 2-73 and Aricept® (donepezil) ∆=7 Model focu

  21. Slide 21: ANAVEX PLUS: Integrated Phase 1b/2 Clinical Development Plan

    Slide 21: ANAVEX PLUS: Integrated Phase 1b/2 Clinical Development Plan

    ANAVEX PLUS: Integrated Phase 1b/2 Clinical Development Plan Advantage: Minimizes timelines and budget Both duration and size of trial would allow for proper data readout With potential for next trial being the pivotal Study Phase 1b/2a Study Phase 2/3 Study* Mild-(moderate) AD patients (~40) Mild-(

  22. Slide 22: Phase 1 Single Dose Completed

    Slide 22: Phase 1 Single Dose Completed

    Phase 1 Single Dose Completed Single ascending dose study of ANAVEX 2-73 in healthy human volunteers Randomized, placebo-controlled study Healthy male volunteers between the ages of 18 and 55 received single, ascending oral doses over the course of the trial Objectives: Define maximum tolerated dose

  23. Slide 23: Financial Summary

    Slide 23: Financial Summary

    Financial Summary Shares Outstanding*: 38.3 Million 52 Week Range*: $0.23-$0.87 Cash @ 3/31/14: $9.2 Million Cash burn 1: ~$60k/ mo. corporate Cash burn 2: ~$500k/ mo. w/ trials Symbol: AVXL *As of 5/14/2014 23

  24. Slide 24: Near-term Milestones

    Slide 24: Near-term Milestones

    Near-term Milestones Secure cGMP manufacturing for drug candidate trial supplies – 2Q 2014 Enroll first patient in Phase 1b/2a study – 2014 Safety and exploratory efficacy Enroll first patient in Phase 2 study – 2015 Ongoing safety and efficacy Potential for first registration study Report data from

  25. Slide 25: Investment Highlights

    Slide 25: Investment Highlights

    Investment Highlights Lead product ANAVEX PLUS directed to Alzheimer‘s disease, a multibillion dollar, poorly served opportunity ANAVEX PLUS poised to enter Phase 2 program Potential to be 1 of 2 FDA registration trials ANAVEX PLUS has a de-risked regulatory pathway ANAVEX PLUS is a “cocktail ” of t

  26. Slide 26: Every 68 seconds someone develops Alzheimer's

    Slide 26: Every 68 seconds someone develops Alzheimer's

    Alzheimer’s Disease … “… Every 68 seconds someone develops Alzheimer’s” ̶ The Alzheimer’s Association … Anavex is working on a potential solution. 26

  27. Slide 27: Contact Us

    Slide 27: Contact Us

    Contact Us Corporate Office: Anavex Life Sciences Corp. 51 West 52nd Street, 7th floor New York, NY 10019 USA Shareholder & Media Relations: Toll-free: 1-866-505-2895 Outside North America: + 1 (416) 489-0092 Email: ir@anavex.com www.anavex.com OTCQB: AVXL 27

Source: Internet Archive copy of anavex.com

More decks from Anavex Life Sciences Corp.

All 35 Anavex Life Sciences decks